Shareholder Trent Miracle Named Plaintiffs’ Co-lead Counsel for Tepezza MDL

ALTON, Ill. – Simmons Hanly Conroy, one of the nation’s largest mass torts firms and a national leader in the legal representation of mesothelioma patients and their families, is pleased to announce that Firm Shareholder Trent B. Miracle has been appointed plaintiffs’ co-lead counsel for the multidistrict litigation (MDL) concerning alleged permanent hearing loss and tinnitus associated with the use of the drug Tepezza.

MDL No. 3079, titled In re: Tepezza Marketing, Sales Practices, and Products Liability Litigation, is set in the U.S. District Court for the Northern District of Illinois before Judge Thomas M. Durkin.

“Trent is an experienced leader in high stakes litigation. He will be a tremendous plaintiffs’ representative and co-lead for the Tepezza MDL,” said Laurence Nassif, Managing Shareholder of Simmons Hanly Conroy.

Miracle said, “It is a privilege to serve as plaintiffs’ co-lead counsel for the Tepezza MDL. I look forward to working to absolutely ensure that people who have suffered harm from this dangerous drug receive the justice they deserve as we seek to hold the drugmaker accountable.”

Manufactured by Horizon Therapeutics, the FDA-approved biologic drug Tepezza is used to treat thyroid eye disease. People who have taken Tepezza and experienced permanent hearing loss or tinnitus have filed lawsuits claiming that the drug’s label failed to warn doctors and patients about the health risks associated with the drug.

Co-chair of Simmons Hanly Conroy’s Complex Litigation Department, Miracle has more than 25 years of experience handling a broad array of mass torts cases, helping thousands of people harmed by dangerous drugs and defective medical devices. Miracle has served on plaintiffs’ steering committees for several MDLs including Yaz, DePuy Hip Replacement and Propecia, among others, and was appointed as co-lead counsel in the MDL involving testosterone replacement therapy.

A national leader in pharmaceutical injury litigation, Simmons Hanly Conroy has secured more than $2 billion in settlements on behalf of its clients harmed by pharmaceutical drugs such as Bextra, Yaz, Vioxx, Ortho Evra and Ephedra, as well as numerous defective medical devices.